表紙
市場調查報告書

複雜性局部疼痛症候群:開發中產品分析

Complex Regional Pain Syndrome - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 465218
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
複雜性局部疼痛症候群:開發中產品分析 Complex Regional Pain Syndrome - Pipeline Review, H1 2020
出版日期: 2020年02月28日內容資訊: 英文 60 Pages
簡介

複雜性局部疼痛症候群(CRPS)是一種慢性疼痛疾病,幾乎都是受到傷害後對手出現影響。CRPS分為兩種類型:無伴隨慢性神經損傷的一型與合併有慢性神經損傷的二型。症狀包括受影響關節的僵硬,指甲和頭髮生長模式的變化,肌肉張力障礙和出汗異常等。治療包括非類固醇系抗發炎藥和類鴉片物質,局部用麻醉霜。

本報告提供複雜性局部疼痛症候群的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

複雜性局部疼痛症候群;概要

治療藥的開發

  • 開發中產品;概要
  • 各企業的開發中產品
  • 各大學/研究機關的開發中產品
  • 企業開發中的治療藥
  • 大學/研究機關開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Abiogen Pharma SpA
  • Axsome Therapeutics, Inc.
  • Grunenthal GmbH
  • Mallinckrodt Plc

藥物簡介

  • hydromorphone hydrochloride
  • neridronic acid
  • NTRX-07
  • Recombinant Protein for CRPS
  • Small Molecules for Pain
  • Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System
  • T-121
  • zoledronic acid

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11948IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Complex Regional Pain Syndrome - Pipeline Review, H1 2020, provides an overview of the Complex Regional Pain Syndrome (Central Nervous System) pipeline landscape.

Complex regional pain syndrome (CRPS) is a chronic pain condition that most often affects one limb usually after an injury. CRPS is divided into two types: CRPS-I (Individuals without a confirmed nerve injury) and CRPS-II (when there is an associated, confirmed nerve injury). Symptoms include stiffness in affected joints, changes in nail and hair growth patterns, dystonia and abnormal sweating pattern. Treatment includes bisphosphonates, non-steroidal anti-inflammatory drugs, opioids and local anesthetic creams.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Complex Regional Pain Syndrome - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Complex Regional Pain Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Complex Regional Pain Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0 and Preclinical stages are 1, 3, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Complex Regional Pain Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Complex Regional Pain Syndrome (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Complex Regional Pain Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Complex Regional Pain Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Complex Regional Pain Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Complex Regional Pain Syndrome (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Complex Regional Pain Syndrome (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Complex Regional Pain Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

  • Global Markets Direct Report Coverage
  • Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Overview
  • Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Companies Involved in Therapeutics Development
  • Allergan Plc
  • Bexson Biomedical Inc
  • Biohaven Pharmaceutical Holding Company Ltd
  • NeuroTherpia Inc
  • Piramal Enterprises Ltd
  • Takeda Pharmaceutical Co Ltd
  • Tetra Bio-Pharma Inc
  • Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Drug Profiles
  • BHV-5000 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • hydromorphone hydrochloride (intrathecal infusion) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ketamine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NTRX-07 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • onabotulinumtoxinA - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PPP-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • soticlestat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Dormant Projects
  • Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Product Development Milestones
  • Featured News & Press Releases
  • Oct 08, 2019: Bexson Biomedical's Chief Scientific Officer speaks to ketamine leaders at ASKP conference
  • Feb 05, 2019: Tetra Bio-Pharma redefines quality standards for pharmaceutical grade cannabis-derived products
  • Mar 14, 2018: Tetra Bio-Pharma Announces FDA Orphan Drug Designation for PPP001 in Treatment of Complex Regional Pain Syndrome
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by Allergan Plc, H1 2020
  • Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by Bexson Biomedical Inc, H1 2020
  • Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2020
  • Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by NeuroTherpia Inc, H1 2020
  • Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by Piramal Enterprises Ltd, H1 2020
  • Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
  • Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Pipeline by Tetra Bio-Pharma Inc, H1 2020
  • Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy) - Dormant Projects, H1 2020

List of Figures

  • Number of Products under Development for Complex Regional Pain Syndrome (Sympathetic Reflex Dystrophy/Reflex Sympathetic Dystrophy), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020